MLi-2, a Potent, Selective, and Centrally Active Compound for Exploring the Therapeutic Potential and Safety of LRRK2 Kinase InhibitionMatthew Fell, John A. Morrow, Christian Mirescu et al.|Journal of Pharmacology and Experimental Therapeutics|2015Cited by 336
Small molecule allosteric inhibitors of RORγt block Th17-dependent inflammation and associated gene expression in vivoSteven A. Saenz, J. Michael Ellis|PLoS ONE|2021Cited by 8
Small molecule allosteric inhibitors of RORγt block Th17-dependent inflammation and associated gene expression in vivoSteven A. Saenz, J. Michael Ellis|bioRxiv (Cold Spring Harbor Laboratory)|2021Cited by 3